2022
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Valdecantos W, Brodovicz K, Lertratanakul A, Strober B. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 8: 56-65. PMID: 39296672, PMCID: PMC11361487, DOI: 10.1177/24755303221146990.Peer-Reviewed Original ResearchPatient-reported outcomesPalmoplantar pustulosisPlaque psoriasisReal-world evidencePsoriasis RegistryDisease burdenPatient stratificationWorse patient-reported outcomesBody surface area involvementGreater impairmentMean overall painSurface area involvementVisual analog scaleRare skin diseaseReal-world studyQuality of lifeLittle real-world evidenceNeutrophilic pustulesOverall painClinical characteristicsPsoriasis AreaAnalog scaleArea involvementDisease characteristicsEffective therapyThe Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Kotowsky N, Strober B. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 71-78. PMID: 39296823, PMCID: PMC11361522, DOI: 10.1177/24755303221079814.Peer-Reviewed Original ResearchPlaque psoriasisReal-world evidenceMore treatment experiencePsoriasis RegistryPustular psoriasisTreatment experiencePatient-reported outcome measuresGeneralized pustular psoriasisCurrent treatment optionsFuture treatment decisionsQuality of lifeGPP treatmentNeutrophilic pustulesPatient sociodemographicsMedian painMedication useNorth American adultsSystemic diseaseDisease characteristicsTreatment optionsRecurrent flaresDisease burdenPatient outcomesTreatment decisionsOutcome measures
2021
25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry
Lebwohl M, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Strober B. 25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab4. DOI: 10.1016/j.jaad.2021.06.042.Peer-Reviewed Original Research26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry
Strober B, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Lebwohl M. 26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab108. DOI: 10.1016/j.jaad.2021.06.451.Peer-Reviewed Original Research
2020
15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry
Bagel J, Behl A, Litman H, Medeiros R, Guo N, Lebwohl M, Strober B. 15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry. Journal Of The American Academy Of Dermatology 2020, 83: ab152. DOI: 10.1016/j.jaad.2020.06.697.Peer-Reviewed Original Research
2018
Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries
Strober B, Crowley J, Langley R, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos W. Systematic review of the real‐world evidence of adalimumab safety in psoriasis registries. Journal Of The European Academy Of Dermatology And Venereology 2018, 32: 2126-2133. PMID: 30067882, DOI: 10.1111/jdv.15203.Peer-Reviewed Original ResearchConceptsMajor cardiac eventsAdverse eventsPsoriasis RegistryReal-world evidenceAdalimumab safetySerious AEsAdult patientsCardiac eventsClinical studiesSafety dataLong-term safety profileCardiovascular-related eventsSerious adverse eventsSerious cardiovascular eventsReal-world safetyLong-term safetyRate of infectionEnglish language manuscriptsCardiovascular eventsSafety profileSerious infectionsAdalimumabClinical practiceEligible papersRegistry